Medtronic reports positive results with Valiant

Medtronic's Valiant thoracic stent graft system delivered positive clinical results through one year of patient follow-up in the company's U.S. pivotal study, VALOR II, according to data presented at a meeting for vascular surgeons. The study met all of its prespecified endpoints. The primary safety and effectiveness endpoints were 12-month all-cause mortality and 12-month successful aneurysm treatment defined as the absence of aneurysm growth (>5 mm) at one and 12 months, and type I and/or type III endoleak for which a secondary procedure was performed or recommended at or before the 12-month visit. Medtronic release

Suggested Articles

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.